Omnicell, Inc. (NASDAQ:OMCL) Receives $54.50 Consensus Price Target from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $54.50.

Several research firms have weighed in on OMCL. Wells Fargo & Company upped their price target on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. Zacks Research downgraded shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Weiss Ratings upgraded shares of Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, February 9th. Finally, Wall Street Zen lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th.

Omnicell Stock Performance

NASDAQ:OMCL opened at $41.10 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.22 and a current ratio of 1.43. The stock has a 50-day simple moving average of $45.05 and a two-hundred day simple moving average of $38.01. The firm has a market capitalization of $1.87 billion, a PE ratio of 1,027.76, a P/E/G ratio of 1.47 and a beta of 0.79. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). The company had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business earned $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Analysts forecast that Omnicell will post 1.09 EPS for the current year.

Insider Buying and Selling

In related news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the transaction, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after purchasing an additional 5,311 shares during the period. Empowered Funds LLC boosted its stake in shares of Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after purchasing an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after buying an additional 4,866 shares during the period. Jane Street Group LLC raised its stake in Omnicell by 201.5% in the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after buying an additional 109,382 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Omnicell during the second quarter worth $282,000. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.